



Start/Search

[Browse by Day](#)[Browse by Program](#)[Browse by Author](#)[Browse by Keyword](#)[Personal Scheduler](#)[ASH Meeting Home](#)[ASH Home](#)

-Author name in bold denotes the presenting author

-Asterisk * with author name denotes a Non-ASH member

denotes an abstract that is clinically relevant.

denotes that this is a recommended PHD Trainee Session.

denotes that this is a ticketed session.

1807 Pharmacokinetic and Safety of CT-P10, a Biosimilar Candidate to the Rituximab Reference Product, in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma (AFL)

Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster I

Saturday, December 3, 2016, 5:30 PM-7:30 PM

Hall GH (San Diego Convention Center)

Bertrand Coiffier¹, **Juan-Manuel Sancho**^{2*}, **Wojciech Jurczak**³, **Jin Seok Kim**^{4*}, **Raj V Nagarkar**^{5*}, **Edvard Zhavrid**^{6*}, **Jose Angel Hernandez Rivas**^{7*}, **Aliaksandr Prokharau**^{8*}, **Mamia Zodelava**^{9*}, **Dzhelil Osmanov**^{10*}, **Michinori Ogura**¹¹, **Christian Buske**¹², **Larry Kwak**^{13*}, **Sang Joon Lee**^{14*}, **Sung Young Lee**^{14*}, **Yun Ju Bae**^{14*} and **Won Seog Kim**¹⁵

¹Hospices Civils de Lyon, Pierre-Benite, France²Hospital Universitario Germans Trias i Pujol, Badalona, Spain³Department of Haematology, Jagiellonian University, Kraków, Poland⁴Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea, The Republic of⁵Curie Manavata Cancer Centre, Nashik, India⁶N.N. Alexandrov Republican Scientific and Practical Centre of Oncology and Medical Radiology, Minsk, Belarus⁷Hospital Universitario Infanta Leonor, Madrid, Spain⁸Minsk City Clinical Oncology Dispensary, Minsk, Belarus⁹M.Zodelava's Hematology Centre, Tbilisi, Georgia¹⁰N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation¹¹Department of Hematology, Tokai Central Hospital, Gifu, Japan¹²Institute of Experimental Cancer Research, University Hospital of Ulm, Ulm, Germany¹³Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA¹⁴CELLTRION, Inc, Incheon, Korea, The Republic of¹⁵Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, The Republic of

Background: CT-P10 is a biosimilar candidate to the reference rituximab product, EU-approved MabThera[®] and US-licensed Rituxan[®]. CT-P10 has an identical amino acid sequence and highly similar physicochemical and in vitro functional properties to its reference drug. In patients with rheumatoid arthritis, CT-P10 has demonstrated compelling similarity in pharmacokinetics (PK), pharmacodynamics (PD), efficacy, safety and immunogenicity (Yoo DH, et al. Arthritis Rheum. 2013;65(10):1736).

Objective: The goal of this study was to demonstrate PK similarity of CT-P10 to rituximab, each administered in combination with cyclophosphamide, vincristine, and prednisone (CVP) in patients with newly diagnosed Advanced Follicular Lymphoma (AFL) (NCT02162771) (Kim WS et al. Blood. 2015;126(23): 5111). The results of PK, PD, safety and immunogenicity up to Core Cycle 4 (12 weeks) are presented here from this ongoing study.

Methods: Patients with AFL were randomized 1:1 to receive infusion (375mg/m²) of either CT-P10 or rituximab, at a 3-week interval, in combination with CVP. PK analysis was conducted in terms of AUC_{tau} and C_{max} at steady state, Core Cycle 4, as primary PK endpoints. PK parameter values considered as outliers determined by robust regression outlier testing were excluded from the pharmacokinetic primary analysis.

Results: In total, 121 patients were randomly assigned to receive either CT-P10 (n=59) or rituximab (n=62) in combination with CVP. Result of CT-P10 PK at Core Cycle 4 was similar to that of rituximab. The ratios (90% CI) of geometric least square means (CT-P10 to rituximab treatment group) were 102.3% (94.1%–111.2%) for AUC_{tau} and 100.7% (93.8%–108.0%) for C_{maxSS} at Core Cycle 4. The 90% CIs of ratio of geometric LS means for both AUC_{tau} and C_{maxSS} were entirely contained within the equivalence margin of 80% to 125% (Table 1 and Figure 1). Mean serum concentrations of the study drug were highly similar for the 2 treatment groups at each time point (Core Cycle 1 to 4).

The B-cell kinetics was similar up to Core Cycle 4 in the 2 treatment groups. Median number of B-cells decreased to below the lower limit of quantification (LLOQ) (20 cells/ μ L) 1 hour after the end of infusion at Core Cycle 1 and remained below the LLOQ at each subsequent cycle, up to and including Core Cycle 4.

The proportion of patients with a positive anti-drug antibody up to Core Cycle 4 at post-treatment visits was similar between the 2 treatment groups; 3/59 (5.1%) patients and 2/62 (3.2%) patients in the CT-P10 and rituximab groups, respectively.

In addition, CT-P10 was well tolerated and the safety profile of CT-P10 up to Core Cycle 4 was similar to that of rituximab. The number of patients who experienced at least 1 treatment emergent adverse event (TEAE) was 43 (72.9%) patients and 41 (66.1%) patients in CT-P10 and rituximab treatment groups, respectively. The proportion of patients who experienced at least 1 treatment emergent serious adverse event considered by the investigator to be related to the study treatment was similar between the 2 treatment groups; 2/59 (3.4%) patients and 2/62 (3.2%) patients in the CT-P10 and rituximab groups, respectively. The frequencies of adverse events special interest (AESI) were similar between the 2 treatment groups (Table 2).

Table 1. Statistical Analysis of Rituximab Pharmacokinetic Primary Endpoints for Core Cycle 4 at Steady State: Pharmacokinetic Population

Parameter (Unit)	Treatment	n	Geometric Least Squares Mean	Ratio (%) of Geometric LS Means	90% Confidence Interval of the Ratio
AUC _{tau} (h × μ g/mL)	CT-P10	50	41011	102.3	94.1-111.2
	Rituximab	56	40099		
C _{maxSS} (μ g/mL)	CT-P10	53	256.19	100.7	93.8-108.0
	Rituximab	56	254.49		

Abbreviations: AUC_{tau}, area under the serum concentration-time curve at steady state; C_{maxSS}, maximum serum concentration at steady state.

Figure 1. Mean (\pm SD) Serum Concentration of Rituximab Versus Time for Cycle 4 at Steady State (Linear Scale): Pharmacokinetic Population




Table 2. The Incidence Rates of Adverse Events Special Interest: Safety Population

Adverse events special interest	CT-P10 (N=59)	Rituximab (N=62)	Total (N=121)
	Number(%) of Patients		
Infusion related reaction	15 (25.4)	13 (21.0)	28 (23.1)
Infection	12 (20.3)	13 (21.0)	25 (20.7)
Progressive multifocal leukoencephalopathy	0	0	0
Serious viral infection	0	0	0
Hepatitis B virus reactivation	0	0	0

Conclusion: This study demonstrated similarity of PK in terms of AUC_{tau} and C_{maxSS} between CT-P10 and rituximab in AFL patients. The B-cell kinetics and immunogenicity were comparable between the two treatment groups. CT-P10 was well tolerated with a safety profile comparable to that of rituximab up to and including Core Cycle 4 (12 weeks).

Disclosures: **Coiffier:** Celltrion, Inc.: Consultancy, Honoraria. **Sancho:** Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celltrion, Inc.: Research Funding; Janssen:

Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; *Sanofi*: Membership on an entity's Board of Directors or advisory committees; *Roche*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. **Jurczak**: *Celltrion, Inc.*: Research Funding; *Gilead Sciences*: Research Funding; *Acerta*: Research Funding; *Bayer*: Research Funding; *Janssen*: Research Funding. **Kim**: *Celltrion, Inc.*: Research Funding. **Nagarkar**: *Celltrion, Inc.*: Research Funding. **Zhavrid**: *Celltrion, Inc.*: Research Funding. **Hernandez Rivas**: *Celltrion, Inc.*: Research Funding. **Prokharau**: *Celltrion, Inc.*: Research Funding. **Zodelava**: *Celltrion, Inc.*: Research Funding. **Osmanov**: *Celltrion, Inc.*: Research Funding. **Ogura**: *SymBio Pharmaceuticals*: Consultancy, Honoraria; *Celltrion, Inc.*: Consultancy, Honoraria. **Buske**: *Celltrion, Inc.*: Consultancy, Honoraria. **Kwak**: *Celltrion, Inc.*: Consultancy. **Kim**: *Celltrion, Inc.*: Consultancy, Honoraria.

See more of: [623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster I](#)
See more of: [Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies](#)
See more of: [Oral and Poster Abstracts](#)

[<< Previous Abstract](#) | [Next Abstract >>](#)

**signifies non-member of ASH*



American Society of Hematology

Helping hematologists conquer blood diseases worldwide.

2021 L Street NW, Suite 900, Washington, DC 20036

Phone 202-776-0544 | Fax 202-776-0545

ASH Home	Research	Education	Advocacy	Meetings	Publications	ASH Store
--------------------------	--------------------------	---------------------------	--------------------------	--------------------------	------------------------------	---------------------------



Copyright © 2016 by American Society of Hematology

[Contact Us](#) | [Privacy Policy](#) | [Terms of Service](#)